The estimated Net Worth of Brian A Markison is at least $10.7 Million dollars as of 27 March 2023. Mr. Markison owns over 13,290 units of Osmotica Pharmaceuticals Plc stock worth over $21,443 and over the last 20 years he sold OSMT stock worth over $6,387,959. In addition, he makes $4,338,620 as Chairman of the Board and Chief Executive Officer at Osmotica Pharmaceuticals Plc.
Brian has made over 21 trades of the Osmotica Pharmaceuticals Plc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 13,290 units of OSMT stock worth $1,078,218 on 27 March 2023.
The largest trade he's ever made was selling 41,812 units of Osmotica Pharmaceuticals Plc stock on 8 September 2022 worth over $3,522,243. On average, Brian trades about 3,550 units every 57 days since 2004. As of 27 March 2023 he still owns at least 19,318 units of Osmotica Pharmaceuticals Plc stock.
You can see the complete history of Mr. Markison stock trades at the bottom of the page.
Brian Markison serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Markison has been a healthcare industry advisor to Avista Capital Partners since September 2012 and has more than 35 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. From July 2011 to July 2012, he served as the President and Chief Executive Officer and member of the board of directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology that was sold to Sandoz Ltd., the generics division of Novartis AG. Before leading Fougera, Mr. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, Inc., which he joined as Chief Operating Officer in March 2004. He was promoted to President and Chief Executive Officer later that year and elected Chairman in 2007. Prior to joining King Pharmaceuticals, Inc., Mr. Markison held various senior leadership positions at Bristol-Myers Squibb Company, including President of Oncology, Virology and Oncology Therapeutics Network President of Neuroscience, Infectious Disease and Dermatology; and Senior Vice President, Operational Excellence and Productivity. He serves as Chairman of the board of Lantheus Holdings, Inc. and is on the board of directors of Cosette Pharmaceuticals, Inc., National Spine and Pain Centers, LLC and Braeburn Pharmaceuticals, Inc. He is also a Director of the College of New Jersey. Mr. Markison received a B.S. degree from Iona College. Mr. Markison is being nominated to serve on our board of directors because of his strong commercial and operational management background and extensive experience in the pharmaceutical industry.
As the Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceuticals Plc, the total compensation of Brian Markison at Osmotica Pharmaceuticals Plc is $4,338,620. There are no executives at Osmotica Pharmaceuticals Plc getting paid more.
Brian Markison is 60, he's been the Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceuticals Plc since 2019. There are 5 older and 9 younger executives at Osmotica Pharmaceuticals Plc. The oldest executive at Osmotica Pharmaceuticals Plc is Fred Weiss, 78, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON ROAD, SOUTH BLDG, BEDFORD, MA, 01730.
Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over $0 worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth $31,350,366 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman, and Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of $1,173,603. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth $100,366.
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include: